Dynamic Technology Lab Private Ltd purchased a new position in shares of PharMerica Corp. (NYSE:PMC) during the second quarter, Holdings Channel reports. The fund purchased 18,740 shares of the company’s stock, valued at approximately $462,000. Dynamic Technology Lab Private Ltd owned 0.06% of PharMerica Corp. at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Teacher Retirement System of Texas increased its stake in shares of PharMerica Corp. by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 4,243 shares of the company’s stock valued at $105,000 after buying an additional 523 shares during the period. Springbok Capital Management LLC increased its stake in shares of PharMerica Corp. by 22.8% in the first quarter. Springbok Capital Management LLC now owns 7,000 shares of the company’s stock valued at $155,000 after buying an additional 1,300 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of PharMerica Corp. by 5.6% in the second quarter. PNC Financial Services Group Inc. now owns 7,474 shares of the company’s stock valued at $185,000 after buying an additional 398 shares during the period. Murphy Michael R acquired a new stake in shares of PharMerica Corp. during the first quarter valued at about $221,000. Finally, BNP Paribas Arbitrage SA increased its stake in shares of PharMerica Corp. by 96.5% in the second quarter. BNP Paribas Arbitrage SA now owns 10,303 shares of the company’s stock valued at $254,000 after buying an additional 5,060 shares during the period. 92.37% of the stock is currently owned by institutional investors and hedge funds.

PharMerica Corp. (NYSE:PMC) opened at 26.574 on Tuesday. The firm has a market capitalization of $817.52 million, a P/E ratio of 27.452 and a beta of 0.87. The firm’s 50-day moving average price is $24.96 and its 200 day moving average price is $24.53. PharMerica Corp. has a one year low of $19.79 and a one year high of $35.81.

PharMerica Corp. (NYSE:PMC) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.47. PharMerica Corp. had a return on equity of 10.00% and a net margin of 1.44%. The company had revenue of $519.60 million for the quarter, compared to the consensus estimate of $508.31 million. During the same quarter last year, the business posted $0.48 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. On average, equities analysts anticipate that PharMerica Corp. will post $2.01 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the company. Zacks Investment Research raised PharMerica Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, September 1st. Bank of America Corp. started coverage on PharMerica Corp. in a research report on Tuesday, June 7th. They issued a “buy” rating and a $32.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. PharMerica Corp. presently has an average rating of “Buy” and an average target price of $31.57.

PharMerica Corp. Company Profile

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

5 Day Chart for NYSE:PMC

Want to see what other hedge funds are holding PMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PharMerica Corp. (NYSE:PMC).

Receive News & Ratings for PharMerica Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.